Alpex Acquisition Corp.

Alopexx, Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, specializes in developing innovative immune-based treatments. The company's mission is to prevent, treat, and mitigate a range of bacterial, fungal, and parasitic infections. Its leading development candidates include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine, which has successfully completed its Phase I first-in-human trial. This vaccine is being investigated for the treatment of various conditions, such as Streptococcus pneumoniae and meningococcal infections, as well as exploring potential applications in Alzheimer's disease and type 1 diabetes mellitus. Another significant asset is F598, a monoclonal antibody that has progressed through Phase I and pilot Phase II studies. This antibody aims to prevent and lessen the impact of gram-negative and gram-positive bacterial infections, alongside fungal infections, particularly those caused by organisms that produce PNAG. Its current application is focused on critically ill patients in intensive care units.